It has been
reported that ZON and some of its metabolites promote the development of hormone-dependent tumors.
The aim of this case-control study was to estimate exposure to ZON and its five metabolites (a-zearalenol
[a-ZOL], b-zearalenol [b-ZOL], a-zearalanol [zeranol, a-ZAL], b-zearalanol [teranol, b-ZAL] and zearalanone
[ZAN]) by measuring urinary concentrations of these compounds, and to evaluate the risk of breast
cancer related to this exposure. Chemical analyses were carried out by liquid–liquid extraction (LLE) and
ultra-high performance liquid chromatography with tandem mass spectrometry detection (UHPLC-MS/
MS). Statistical analyses were performed in order to determine the association between exposure to these
compounds and the development of breast cancer. Crude and adjusted odds ratios (ORs) with 95% confidence
intervals (CIs) were calculated by unconditional logistic regression to estimate the magnitude of
the associations. The obtained results (adjusted OR = 1.54, 95% CI = 1.10–2.77) suggest a potential role of
a-ZAL in the risk of developing breast cancer.
It has been
reported that ZON and some of its metabolites promote the development of hormone-dependent tumors.
The aim of this case-control study was to estimate exposure to ZON and its five metabolites (a-zearalenol
[a-ZOL], b-zearalenol [b-ZOL], a-zearalanol [zeranol, a-ZAL], b-zearalanol [teranol, b-ZAL] and zearalanone
[ZAN]) by measuring urinary concentrations of these compounds, and to evaluate the risk of breast
cancer related to this exposure. Chemical analyses were carried out by liquid–liquid extraction (LLE) and
ultra-high performance liquid chromatography with tandem mass spectrometry detection (UHPLC-MS/
MS). Statistical analyses were performed in order to determine the association between exposure to these
compounds and the development of breast cancer. Crude and adjusted odds ratios (ORs) with 95% confidence
intervals (CIs) were calculated by unconditional logistic regression to estimate the magnitude of
the associations. The obtained results (adjusted OR = 1.54, 95% CI = 1.10–2.77) suggest a potential role of
a-ZAL in the risk of developing breast cancer.
การแปล กรุณารอสักครู่..
